Having shown the significant role of changes in the number of CC3+ cells caused by treatment with baseline serum samples in predicting IFN-α–induced depression, we subsequently investigated whether changes in the neurogenic markers DCX and MAP2, as well as the apoptotic marker CC3 detected during the differentiation stage, were predictive of later IFN-α–induced depression. Here, MAP2 is linked to depressive symptom measurement.